By Dr. Priyom Bose, Ph.D. By replacing both breathing and circulatory buffering, a novel artificial lung bought critical time after lung removal, revealed irreversible damage, and made transplantation ...
The ATS/ERS 2025 statement on interstitial pneumonia classification updates the 2013 statement, with insights on secondary ...
The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...
Scientists were certain that nanoplastics (synthetic polymers ranging from 1 nm to 1 μm, according to the National ...
Invisible particles in the air are not just irritating our lungs, they are quietly rewiring the immune system that is ...
Trained immunity enhances innate immune responses, yet a Western lifestyle may lead to maladaptive trained immunity and drive non-communicable diseases.
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc.
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, ...